MX2016012124A - Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos. - Google Patents

Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.

Info

Publication number
MX2016012124A
MX2016012124A MX2016012124A MX2016012124A MX2016012124A MX 2016012124 A MX2016012124 A MX 2016012124A MX 2016012124 A MX2016012124 A MX 2016012124A MX 2016012124 A MX2016012124 A MX 2016012124A MX 2016012124 A MX2016012124 A MX 2016012124A
Authority
MX
Mexico
Prior art keywords
composition
same
antibodies against
against immunogenic
immunogenic glycopeptides
Prior art date
Application number
MX2016012124A
Other languages
English (en)
Inventor
Chang Chih-Long
Wu Chao-Chih
Original Assignee
Mackay Medical Found The Presbyterian Church In Taiwan Mackay Memorial Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mackay Medical Found The Presbyterian Church In Taiwan Mackay Memorial Hospital filed Critical Mackay Medical Found The Presbyterian Church In Taiwan Mackay Memorial Hospital
Publication of MX2016012124A publication Critical patent/MX2016012124A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001173—Globo-H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen en la presente anticuerpos que se unen específicamente a al menos un epítopo definido por el glicopéptido inmunogénico. Otros aspectos de la presente descripción son una composición farmacéutica que comprende el anticuerpo; y un método para prevenir y/o tratar cáncer Globo H positivo.
MX2016012124A 2014-03-19 2015-03-19 Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos. MX2016012124A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461955216P 2014-03-19 2014-03-19
PCT/US2015/021413 WO2015143123A2 (en) 2014-03-19 2015-03-19 Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof

Publications (1)

Publication Number Publication Date
MX2016012124A true MX2016012124A (es) 2017-04-06

Family

ID=54145306

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012124A MX2016012124A (es) 2014-03-19 2015-03-19 Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.

Country Status (11)

Country Link
US (4) US20170143810A1 (es)
EP (2) EP3119432B1 (es)
JP (1) JP2017518958A (es)
KR (1) KR20170003912A (es)
CN (2) CN107073088A (es)
AU (1) AU2015231256A1 (es)
CA (2) CA2943334A1 (es)
IL (1) IL247659A0 (es)
MX (1) MX2016012124A (es)
TW (2) TW201622743A (es)
WO (2) WO2015143126A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272144B2 (en) 2013-07-31 2019-04-30 Bioventures, Llc Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens
SG11201510740YA (en) 2013-09-17 2016-01-28 Obi Pharma Inc Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
KR20170003912A (ko) 2014-03-19 2017-01-10 매카이 메디컬 파운데이션 더 프레즈비티리언 처치 인 타이완 매카이 메모리얼 호스피탈 면역원성 당펩타이드에 대한 항체, 이를 포함하는 조성물 및 이의 용도
EP3662928A1 (en) * 2014-04-10 2020-06-10 OBI Pharma Inc. Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof
JP2018532990A (ja) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド グリカンアレイおよび使用の方法
US20180264093A1 (en) * 2015-09-18 2018-09-20 Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation Immunogenic glycopeptide compounds, pharmaceutical compositions and uses thereof
CN108472362B (zh) * 2015-10-07 2022-03-29 台湾浩鼎生技股份有限公司 新颖糖类抗体、医药组成物及其用途
TWI780045B (zh) 2016-03-29 2022-10-11 台灣浩鼎生技股份有限公司 抗體、醫藥組合物及方法
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
AU2017252128B2 (en) 2016-04-22 2024-06-06 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
KR20230117482A (ko) 2016-07-27 2023-08-08 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
JP7121724B2 (ja) 2016-07-29 2022-08-18 オービーアイ ファーマ，インコーポレイテッド ヒト抗体、医薬組成物及び方法
WO2018054353A1 (en) * 2016-09-23 2018-03-29 Chang, Chih-Long Anti-globo h antibodies
WO2018094414A1 (en) 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
CA3064443A1 (en) * 2017-05-24 2018-11-29 Development Center For Biotechnology Humanized antibodies against globo h and uses thereof in cancer treatments
CN111093701A (zh) * 2017-06-15 2020-05-01 财团法人生物技术开发中心 含有抗globo h抗体的抗体药物偶联物及其用途
CA3068056A1 (en) * 2017-06-22 2018-12-27 Development Center For Biotechnology Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecifc antibody and uses thereof in cancer therapy
US11155638B2 (en) * 2018-05-08 2021-10-26 Rhode Island Hospital Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
KR20210031651A (ko) * 2018-06-01 2021-03-22 오비아이 파머 인코퍼레이티드 항-음성 면역 관문 항체와 항-globo h 또는 항-ssea-4 항체를 사용한 병용 요법
TWI853822B (zh) 2018-06-27 2024-09-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
EP3852779A4 (en) * 2018-09-17 2022-06-08 Abcuro, Inc. ANTI-KLRG1 ANTIBODIES
EP3799881A1 (en) 2019-10-04 2021-04-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Single domain antibodies specifically binding globo - series glycans
CN110665001A (zh) * 2019-11-14 2020-01-10 上海农林职业技术学院 一种水性复合佐剂、其应用及猫用疫苗
KR102506295B1 (ko) * 2020-08-28 2023-03-08 국립암센터 디그옥시제닌에 대한 인간화 항체 및 이의 용도
CN112675298B (zh) * 2020-12-28 2024-05-03 中国医学科学院医学生物学研究所 一种免疫佐剂、含有所述免疫佐剂的疫苗及制备方法和应用
CN118949024B (zh) * 2024-08-05 2025-06-10 成都迈科康生物科技有限公司 免疫调节剂在制备动物癌症治疗的组合物中的应用
WO2026052782A1 (en) 2024-09-06 2026-03-12 Tacalyx Gmbh Anti-globo h antibodies

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT735893E (pt) 1993-09-14 2009-03-06 Pharmexa Inc Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária
US20050049197A1 (en) 1993-09-14 2005-03-03 Epimmune Inc. Induction of immune response against desired determinants
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
US6544952B1 (en) 1994-03-15 2003-04-08 Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the globo-H epitope and uses thereof
PT876398E (pt) * 1996-01-24 2002-12-31 Epimmune Inc Inducao de respostas imunitarias contra determinantes desejados
US6676946B2 (en) 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB0029360D0 (en) * 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20070178095A1 (en) 2004-03-23 2007-08-02 Eli Lilly And Company Anti-myostatin antibodies
JP4702950B2 (ja) * 2005-03-28 2011-06-15 キヤノン株式会社 電子写真感光体、プロセスカートリッジおよび電子写真装置、ならびに、電子写真感光体の製造方法
US20070202578A1 (en) 2005-08-26 2007-08-30 Centre National De La Recherche Scientifique (Cnrs) Production of globosides oligosaccharides using metabolically engineered microorganisms
ES2533464T3 (es) * 2005-10-06 2015-04-10 Eli Lilly And Company Anticuerpos anti-miostatina
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
EP2242773B1 (en) 2008-02-11 2017-06-14 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
WO2009137677A2 (en) 2008-05-07 2009-11-12 Innovative Biosensors, Inc. Reagents, methods, and systems for detecting methicillin-resistant staphylococcus
WO2010005735A2 (en) * 2008-06-16 2010-01-14 Academia Sinica Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment
ES2477549T3 (es) 2008-06-16 2014-07-17 Academia Sinica Diagnóstico del cáncer según la concentración de anticuerpos contra Globo H y sus fragmentos
US7928077B2 (en) 2008-07-11 2011-04-19 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies
AU2009268349C1 (en) 2008-07-11 2015-01-22 Sloan-Kettering Institute For Cancer Research Glycopeptide constructs and uses thereof
WO2010127180A2 (en) 2009-04-30 2010-11-04 University Of Rochester Dc-stamp antibodies
CN102215862B (zh) * 2009-06-16 2016-04-06 中央研究院 Globo h及含新颖糖脂质佐剂的相关抗癌疫苗
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
ES2616258T3 (es) * 2010-03-15 2017-06-12 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Péptidos, conjugados y métodos para aumentar la inmunogenicidad de una vacuna
CA2794851A1 (en) 2010-04-02 2011-10-06 Kalobios Pharmaceuticals, Inc. Generation of antibodies to an epitope of interest
BR112012025730B1 (pt) * 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
CN103209701B (zh) 2010-06-11 2016-08-03 乔治亚大学研究基金公司 免疫原性疫苗
NZ604089A (en) 2010-06-11 2015-03-27 Sloan Kettering Inst Cancer Multivalent glycopeptide constructs and uses thereof
LT2852615T (lt) 2012-05-22 2019-02-11 Bristol-Myers Squibb Company Il-17a/f il-23 bispecifiniai antikūnai ir jų panaudojimai
MX370720B (es) 2012-12-21 2019-12-20 Aveo Pharmaceuticals Inc Anticuerpos anti-gdf15.
EP2941436B1 (en) 2013-01-04 2020-12-02 OBI Pharma, Inc. Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
SG11201510740YA (en) 2013-09-17 2016-01-28 Obi Pharma Inc Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
WO2015054600A2 (en) 2013-10-10 2015-04-16 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
KR20170003912A (ko) 2014-03-19 2017-01-10 매카이 메디컬 파운데이션 더 프레즈비티리언 처치 인 타이완 매카이 메모리얼 호스피탈 면역원성 당펩타이드에 대한 항체, 이를 포함하는 조성물 및 이의 용도
EP3662928A1 (en) 2014-04-10 2020-06-10 OBI Pharma Inc. Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
US9828436B2 (en) 2017-11-28
US20170143810A1 (en) 2017-05-25
US20180371103A1 (en) 2018-12-27
CN107073088A (zh) 2017-08-18
US20170107297A1 (en) 2017-04-20
WO2015143123A2 (en) 2015-09-24
TWI681972B (zh) 2020-01-11
KR20170003912A (ko) 2017-01-10
CN106456766B (zh) 2020-03-10
US20170362337A1 (en) 2017-12-21
AU2015231256A1 (en) 2016-09-22
US9951143B2 (en) 2018-04-24
WO2015143126A1 (en) 2015-09-24
EP3119424A4 (en) 2017-09-13
WO2015143123A3 (en) 2015-11-26
IL247659A0 (en) 2016-11-30
CA2943333A1 (en) 2015-09-24
CN106456766A (zh) 2017-02-22
TW201623336A (zh) 2016-07-01
JP2017518958A (ja) 2017-07-13
EP3119424A1 (en) 2017-01-25
EP3119432A2 (en) 2017-01-25
TW201622743A (zh) 2016-07-01
CA2943334A1 (en) 2015-09-24
EP3119432B1 (en) 2020-01-08
EP3119432A4 (en) 2017-09-13

Similar Documents

Publication Publication Date Title
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CR20230477A (es) MOLÉCULAS DE ANTICUERPO QUE SE UNEN A CD73 Y USOS DE LAS MISMAS (Divisional Exp. 2019-0593)
CL2019003657A1 (es) Anticuerpos que se unen específicamente a cd38 útiles para mejorar una respuesta inmune en un paciente. (divisional solicitud 201703275)
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
ES3052034T3 (en) Humanized or chimeric cd3 antibodies
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
BR112017001588A2 (pt) conjugados de anticorpo/fármaco anti-cdh6
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
CO2017010618A2 (es) Anticuerpos contra icos
ECSP17001673A (es) Anticuerpos monoclonales contra el epitope de her2
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
CU24498B1 (es) Anticuerpos de factor xi
CU20160101A7 (es) Inmunoglobulina con fab en tándem
AR104847A1 (es) Formulación de anticuerpo anti-cgrp
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
MX2015016627A (es) Vacuna para la malaria.
CO2019011640A2 (es) Métodos y composiciones para la reducción de la inmunogenicidad
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
MX2017007595A (es) Inmunoterapia para enfermedad angiogenica.
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
MX2018013222A (es) Anticuerpos de interferon beta y usos de los mismos.
UY36820A (es) Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por vrsh